Vitale Cristiana, Ilaria Spoletini, Rosano Giuseppe Mc
Centre for Clinical and Basic Research, Department of Medical Sciences, IRCCS San Raffaele Pisana Rome, Italy.
Card Fail Rev. 2018 May;4(1):25-27. doi: 10.15420/cfr.2018:8:2.
Heart failure (HF) is characterised by exercise intolerance, which substantially impairs quality of life (QOL) and prognosis. The aim of this review is to summarise the state of the art on pharmacological interventions that are able to improve exercise capacity in HF. Ivabradine, trimetazidine and intravenous iron are the only drugs included in the European Society of Cardiology HF guidelines that have consistently been shown to positively affect functional capacity in HF. The beneficial effects on HF symptoms, physical performance and QOL using these pharmacological approaches are described.
心力衰竭（HF）的特征是运动耐量下降，这严重损害了生活质量（QOL）和预后。本综述的目的是总结能够改善HF患者运动能力的药物干预的最新情况。伊伐布雷定、曲美他嗪和静脉铁剂是欧洲心脏病学会HF指南中仅有的几种 consistently been shown to positively affect functional capacity in HF的药物。文中描述了使用这些药物方法对HF症状、身体机能和生活质量的有益影响。
原文中“consistently been shown to positively affect functional capacity in HF”表述不太准确完整，推测可能是“一直被证明能对心力衰竭患者的功能能力产生积极影响” ，但按要求未添加解释。
